Walleye Capital’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
Other funds holding LYEL
CUAMC
PFSRSONJ
SCM
GI
Walleye Capital's LYEL Position: Q2 2026 in Review
Walleye Capital reduced its Lyell Immunopharma (LYEL) stake by 53% in Q2 2026, selling an estimated $213K and leaving 10,451 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3690.
Walleye Capital first reported a position in LYEL in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.62M in Q3 2022. 8 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.
- Walleye Capital held 10,451 shares of Lyell Immunopharma worth $147K as of Q2 2026.
- Walleye Capital sold 11,756 Lyell Immunopharma shares in Q2 2026, an estimated $213K.
- Lyell Immunopharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3690 holding.
- Walleye Capital first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 7 quarters since.
- Walleye Capital's Lyell Immunopharma position peaked at $1.62M in Q3 2022.
- 8 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.